Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Todd Wolynn

Pediatrics Pittsburgh, PA Medical Doctor

NPI 1205835592 CMS profile 397362

810 Clairton Blvd, Pittsburgh, PA 15236

Open in the dashboard

General payments

$275,309

226 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Todd Wolynn of Pittsburgh, PA is reported in the CMS Open Payments database as having received $275,309 across 226 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $61,820 43
2024 General $35,786 33
2023 General $32,067 24
2022 General $20,835 18
2021 General $27,086 17
2020 General $31,422 19
2019 General $66,293 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Todd Wolynn
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Todd Wolynn were reported at $61,820. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Todd Wolynn Pediatrics median Middle half National median
2019 $66,293 $86 $31–$183 $163
2020 $31,422 $49 $22–$110 $114
2021 $27,086 $68 $27–$158 $132
2022 $20,835 $77 $30–$173 $149
2023 $32,067 $88 $33–$190 $160
2024 $35,786 $94 $34–$206 $164
2025 $61,820 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $98,680 97 payments
  2. Sanofi Pasteur Inc. $87,509 54 payments
  3. Moderna TX, Inc. $39,505 33 payments
  4. Seqirus USA Inc $18,678 9 payments
  5. Pfizer Inc. $17,342 18 payments
  6. Novavax Inc $13,573 14 payments
  7. GlaxoSmithKline, LLC. $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $151,661 63 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $78,240 30 payments
  3. Travel and Lodging $40,978 68 payments
  4. Food and Beverage $4,430 65 payments
Products named General payments · program years 2019–2025
  1. NO PRODUCT DISCUSSED $30,894 22 payments
  2. GARDASIL 9 $20,794 14 payments
  3. ENFLONSIA $16,187 13 payments
  4. ABRYSVO $13,888 11 payments
  5. NOVAVAX COVID-19 VACCINE, ADJUVANTED $13,573 14 payments
  6. Moderna Covid-19 Vaccine $9,262 10 payments
  7. BEYFORTUS $9,008 4 payments
  8. FLUCELVAX QUADRIVALENT $8,643 4 payments
  9. FLUZONE QUADRIVALENT $5,962 8 payments
  10. mResvia $5,823 1 payment
  11. Other $10,900 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

226 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record